Xenon Pharmaceuticals Inc. (NASDAQ:XENE) tinted gains of +7.22% (+0.65 points) to US$9.65. The volume of 1.88 Million shares climbed down over an trading activity of 235.59 Million shares. EPS ratio determined by looking at last 12 month figures is -1.5. Over the same time span, the stock marked US$11 as its best level and the lowest price reached was US$2.1. The corporation has a market cap of US$129.21 Million.
Xenon Pharmaceuticals Inc. (NASDAQ:XENE)’s earnings per share has been growing at a -40 percent rate over the past 5 year when average revenue increase was noted as -53.5 percent. The return on equity ratio or ROE stands at -78.9 percent while most common profitability ratio return on investment (ROI) was -76.3 percent. The company’s institutional ownership is monitored at 62.8 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 0 percent gross margin.
Daily Analyst Recommendations
A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 2 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 0 think it is Hold. Recently, analysts have updated the overall rating to 1.33. 1 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) is worth US$27.29 Million and has recently risen 7.13% to US$0.88. The latest exchange of 1.1 Million shares is below its average trading activity of 652.46 Million shares. The day began at US$0 but the price moved to US$0.87 at one point during the trading and finally capitulating to a session high of US$0.87. The stock tapped a 52-week high of US$3.78 while the mean 12-month price target for the shares is US$5.17.
Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 1.79, and a price to sales ratio of 54.57. For the past 5 years, the company’s revenue has grown 0%, while the company’s earnings per share has grown -2.2%. With an institutional ownership near 26.8%, it carries an earnings per share ratio of -1.16.
Inside Look At Analysts Reviews
Latest analyst recommendations could offer little help to investors. The stock is a Buy among 3 brokerage firms polled by Factset Research. At present, 0 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 0 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 1.